Brokers Set Expectations for SCYNEXIS Q1 Earnings

SCYNEXIS, Inc. (NASDAQ:SCYX) – Research analysts at Brookline Capital Acquisition issued their Q1 2026 earnings per share estimates for shares of SCYNEXIS in a research note issued to investors on Monday, March 9th. Brookline Capital Acquisition analyst K. Dolliver anticipates that the company will post earnings per share of ($0.10) for the quarter. Brookline Capital Acquisition has a “Buy” rating on the stock. Brookline Capital Acquisition also issued estimates for SCYNEXIS’s Q2 2026 earnings at ($0.10) EPS, Q3 2026 earnings at ($0.10) EPS, Q4 2026 earnings at ($0.05) EPS and FY2030 earnings at $0.46 EPS.

Other equities research analysts have also issued reports about the company. Wall Street Zen raised SCYNEXIS from a “hold” rating to a “strong-buy” rating in a research report on Saturday. Weiss Ratings reiterated a “sell (d-)” rating on shares of SCYNEXIS in a report on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, SCYNEXIS has a consensus rating of “Hold” and an average price target of $3.00.

SCYNEXIS Stock Up 4.6%

NASDAQ:SCYX opened at $0.90 on Wednesday. SCYNEXIS has a twelve month low of $0.57 and a twelve month high of $1.31. The company has a fifty day moving average of $0.73 and a 200-day moving average of $0.75. The firm has a market capitalization of $40.18 million, a P/E ratio of -5.29 and a beta of 1.32.

SCYNEXIS (NASDAQ:SCYX) last released its quarterly earnings data on Wednesday, March 4th. The company reported $0.25 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.04). SCYNEXIS had a negative net margin of 41.79% and a negative return on equity of 25.52%. The business had revenue of $17.20 million during the quarter, compared to analyst estimates of $8.10 million.

Hedge Funds Weigh In On SCYNEXIS

A number of institutional investors have recently modified their holdings of SCYX. Jane Street Group LLC purchased a new stake in SCYNEXIS during the 2nd quarter worth approximately $27,000. Sequoia Financial Advisors LLC purchased a new position in shares of SCYNEXIS in the 3rd quarter valued at about $41,000. GSA Capital Partners LLP raised its position in shares of SCYNEXIS by 95.2% during the 3rd quarter. GSA Capital Partners LLP now owns 104,423 shares of the company’s stock worth $80,000 after acquiring an additional 50,916 shares in the last quarter. Bridgeway Capital Management LLC lifted its holdings in shares of SCYNEXIS by 4.2% in the 2nd quarter. Bridgeway Capital Management LLC now owns 368,180 shares of the company’s stock valued at $248,000 after purchasing an additional 14,689 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of SCYNEXIS by 7.1% during the fourth quarter. Geode Capital Management LLC now owns 449,223 shares of the company’s stock worth $284,000 after buying an additional 29,775 shares during the last quarter. Hedge funds and other institutional investors own 54.37% of the company’s stock.

SCYNEXIS Company Profile

SCYNEXIS, Inc is a late‐stage biopharmaceutical company focused on developing and commercializing novel anti‐infective therapies. Headquartered in Jersey City, New Jersey, the company’s primary research and development efforts center on combating invasive and chronic fungal infections, an area of high unmet medical need. SCYNEXIS’s scientific platform is built around its proprietary triterpenoid class of antifungals, which are designed to address resistance and safety limitations associated with existing treatments.

The company’s lead product candidate, ibrexafungerp, represents the first oral glucan synthase inhibitor to reach clinical development.